Spotlight On... China hunts for $88M in vaccines diverted to black market; Indian court halts ban on Pfizer, Abbott meds; Kite Pharma names Moore as EVP; and more...

Chinese authorities have arrested a mother-and-daughter team that is accused of illegally buying nearly $90 million worth of vaccines from producers and selling them on the black market. Authorities are now trying to track down the meds, which they believe were not properly stored and shipped before being sold. More from FiercePharmaAsia

> The high court in Delhi has stopped Indian drug regulators from banning hundreds of drugs including cough meds with codeine made by Pfizer ($PFE) and Abbott Laboratories ($ABT). Story

> Kite Pharma ($KITE) named Tim Moore as executive vice president of its technical operations. Moore will be responsible for product development, manufacturing, supply chain, quality assurance and end-to-end process optimization for its engineered T-cell products. Announcement

> Pfizer's Hospira unit is recalling a lot of 8.4% sodium bicarbonate injection after receiving a complaint of particulate in a single-dose glass flip top vial. MedWatch release

> The Associated Chambers of Commerce of India forecasts that India's bulk drug sales will grow by 12% to 14% through the 2018-2019 fiscal year. Report

Suggested Articles

The antidepressant Zoloft and its generics are in short supply as the COVID-19 pandemic has caused higher demand and manufacturing interruptions.

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.